Results 1 to 10 of about 53,802 (245)

Association of clinico-pathological and immunohistochemical prognostic parameters with presence of ductal carcinoma in-situ in an invasive ductal carcinoma of breast

Journal of Pathology of Nepal, 2023
Background: The clinical outcome of breast carcinoma varies in each individual due to its molecular heterogeneity. There is a rising interest in whether the associated ductal carcinoma in-situ in invasive ductal carcinoma of breast affects the prognosis ...
Dhivya Balaiya, Anitha Chellam Annadurai, Jayakarthiga Subbiah Rajasekaran   +2 more
doaj   +1 more source

Immunohistochemical Expression of p63 in Benign and Malignant Breast Lesions [PDF]

Journal of Clinical and Diagnostic Research, 2021
Introduction: Breast carcinoma demands attention as it causes high morbidity and mortality. It is important to recognise benign lesions to distinguish them from in situ and invasive breast cancer and to assess a patient’s risk of developing breast ...
Abhishek Saini, Swaran Kaur Saluja, MK Garg, Deepti Agarwal, Amrita Kulhri, Anjali Sindhu, Smriti Singh   +6 more
doaj   +1 more source

An Unusual Presentation of Extensive Ductal Carcinoma in Situ Accompanying Invasive Ductal Carcinoma on MRI: A Case Report

대한영상의학회지, 2022
The incidence of ductal carcinoma in situ has increased with the rise in screening mammography; currently, ductal carcinoma in situ constitutes 20%–25% of all breast cancers, and up to half of them may become invasive.
Yeon Jung Kim, Hyun Kyung Jung, Woogyeong Kim
doaj   +1 more source

Profile of Digital Mammography Findings in Patients with Histopathologically Proven Ductal Carcinoma in Situ (DCIS)

Galician Medical Journal, 2020
Breast carcinoma is a heterogeneous group of tumors with a wide spectrum of clinical presentations, lesion characterization and diagnostic evaluation.
Ankit Prabhakar, Dawood Iqbal Wani, Shivani Sharma, Sajjad Ahmad Dar, Shaafiya Ashraf   +4 more
doaj   +1 more source

Potential biomarkers of ductal carcinoma in situ progression

BMC Cancer, 2020
Background Ductal carcinoma in situ is a non-obligate precursor of invasive breast carcinoma and presents a potential risk of over or undertreatment. Finding molecular biomarkers of disease progression could allow for more adequate patient treatment.
Raquel Spinassé Dettogni, Elaine Stur, Ana Carolina Laus, René Aloísio da Costa Vieira, Márcia Maria Chiquitelli Marques, Iara Viana Vidigal Santana, José Zago Pulido, Laura Fregonassi Ribeiro, Narelle de Jesus Parmanhani, Lidiane Pignaton Agostini, Raquel Silva dos Reis, Eldamária de Vargas Wolfgramm dos Santos, Lyvia Neves Rebello Alves, Fernanda Mariano Garcia, Jéssica Aflávio Santos, Diego do Prado Ventorim, Rui Manuel Reis, Iúri Drumond Louro   +17 more
doaj   +1 more source

The role of MRI and clinicopathologic features in predicting the invasive component of biopsy-confirmed ductal carcinoma in situ

BMC Medical Imaging, 2020
Background The upgrade rate of biopsy-confirmed ductal carcinoma in situ (DCIS) to invasive carcinoma is up to 50% on final pathology. We investigated MRI and clinicopathologic predictors of the invasive components of DCIS diagnosed by preoperative ...
Ga Young Yoon, Woo Jung Choi, Joo Hee Cha, Hee Jung Shin, Eun Young Chae, Hak Hee Kim   +5 more
doaj   +1 more source

A clinical radiomics nomogram preoperatively to predict ductal carcinoma in situ with microinvasion in women with biopsy-confirmed ductal carcinoma in situ: a preliminary study

BMC Medical Imaging, 2023
Purpose To predict ductal carcinoma in situ with microinvasion (DCISMI) based on clinicopathologic, conventional breast magnetic resonance imaging (MRI), and dynamic contrast enhanced MRI (DCE-MRI) radiomics signatures in women with biopsy-confirmed ...
Zhou Huang, Xue Chen, Nan Jiang, Su Hu, Chunhong Hu   +4 more
doaj   +1 more source

Cystic hypersecretory carcinoma with invasion: Case series on a rare variant of carcinoma breast

Indian Journal of Pathology and Microbiology, 2022
Background: Cystic Hypersecretory Carcinoma (CHC) is a rare subset of breast carcinoma. It is part of a spectrum of cystic hypersecretory lesions which includes cystic hypersecretory hyperplasia (CHH), CHH with atypia, CHC in situ and CHC with invasion ...
Hibu Yami, Renu Thambi, P V Priya, Sankar Sundaram   +3 more
doaj   +1 more source

Does Existence of Ductal Carcinoma In Situ Accompanying Invasive Ductal Carcinoma Lead to Different Clinicopathological Features and Clinical Outcome? Report of a Breast Cancer Registry [PDF]

Middle East Journal of Cancer, 2022
Background: Ductal carcinoma in situ (DCIS) is widely recognized as the precursor of invasive ductal carcinoma (IDC). We aimed to compare clinicopathological characteristics and prognosis between IDC with and without coexisting DCIS stratified by ...
Sedigheh Tahmasebi, Baharak Shahin, Masoumeh Ghoddusi Johari, Majid Akrami, Vahid Zanguri, Abdolrasoul Talei, Zahra Keumarsi, Nazanin Karimaghaei   +7 more
doaj   +1 more source

Clinicopathological features and prognostic differences of ductal carcinoma in situ with ductal carcinoma in situ with microinvasion

Di-san junyi daxue xuebao, 2020
Objective To determine the clinicopathological features and prognostic differences between ductal carcinoma in situ (DCIS) and ductal carcinoma in situ with microinvasion (DCIS-MI) of breast cancer. Methods A cohort of 489 female patients with surgically
LIU Jing, ZHANG Ye, YAN Wenting, ZHONG Ling, TAN Xuanni   +4 more
doaj   +1 more source